Serum total indoxyl sulfate and clinical outcomes in hemodialysis patients: results from the Japan Dialysis Outcomes and Practice Patterns Study.

Journal: Clinical kidney journal
Published Date: Jul 31, 2020

Abstract

BACKGROUND: Uremic toxins are associated with various chronic kidney disease-related comorbidities. Indoxyl sulfate (IS), a protein-bound uremic toxin, reacts with vasculature, accelerating atherosclerosis and/or vascular calcification in animal models. Few studies have examined the relationship of IS with clinical outcomes in a large cohort of hemodialysis (HD) patients.

Authors

  • Suguru Yamamoto
    Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
  • Douglas S Fuller
    Arbor Research Collaborative for Health, Ann Arbor, MI, USA.
  • Hirotaka Komaba
    Division of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine, Isehara, Japan.
  • Takanobu Nomura
    Medical Affairs, Kyowa Kirin Co. Ltd, Tokyo, Japan.
  • Ziad A Massy
    Division of Nephrology, Ambroise Paré University Medical Center, APHP, Boulogne Billancourt, Paris, France.
  • Brian Bieber
    Arbor Research Collaborative for Health, Ann Arbor, Michigan.
  • Bruce Robinson
    Arbor Research Collaborative for Health, Ann Arbor, MI, USA.
  • Ronald Pisoni
    Arbor Research Collaborative for Health, Ann Arbor, MI, USA.
  • Masafumi Fukagawa
    Division of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine, Isehara, Japan.

Keywords

No keywords available for this article.

External Resources

Popular Topics
Recent Journals